corilagin has been researched along with Sepsis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, G; Liao, J; Su, X; Tian, T; Wang, H; Wang, Y; Wu, S; Yan, L; Ye, J; Zhang, C | 1 |
| Dong, JH; Guo, YJ; Li, HR; Liu, J; Luo, T; Wu, F; Zhang, SL; Zhao, L | 1 |
2 other study(ies) available for corilagin and Sepsis
| Article | Year |
|---|---|
Corilagin alleviates LPS-induced sepsis through inhibiting pyroptosis via targeting TIR domain of MyD88 and binding CARD of ASC in macrophages.
Topics: Animals; Caspase Activation and Recruitment Domain; Chromatography, Liquid; Inflammasomes; Lipopolysaccharides; Macrophages; Mice; Myeloid Differentiation Factor 88; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Sepsis; Tandem Mass Spectrometry | 2023 |
Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways.
Topics: Animals; Glucosides; Humans; Hydrolyzable Tannins; Interleukin-1beta; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Myeloid Differentiation Factor 88; RAW 264.7 Cells; Sepsis; Signal Transduction; Toll-Like Receptor 4 | 2017 |